Attendee search 

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class

Leader in consensus forecast analysis of the biotech and pharma sector providing trusted insight into global performance to 2024.

Senior Consultant at Nicholas Hall Consultancy. I am the Head the M&A and Licensing department as well as manage strategic consultancy projects (e.g. market entry, product launches, pricing, etc). I, along with my team have helped global pharma companies and private equity firms find suitable acquisition and licensing opportunities. Let's meet to discuss how Nicholas Hall Consultancy can help you. 

Specialties: Business Development, Licensing and Market Research support, Alliance Management and Customer Relations to the Biotech, Medtech, Pharmaceutical and Life Sciences Industries, and Start-Up Coaching.

www.linkedin.com/in/simon-bennett-0390796

1.  Looking for co-investment opportunities under TPI's i2020 Accelerator scheme: early-stage, seed round, small molecule focus

2.  Looking for assets for licensing for clients, including: rare disease assets (except cell & gene therapy), CVD, pain management, respiratory, innovative technologies, 505(b)(2) products

3.  Meeting companies interested in state-of-the -art machine learning solutions for drug discovery

4.  Meeting companies interested in acquiring antibody libraries

5.  Meeting companies interested in acquiring a phase II ready asset in multiple myeloma

6.  Meeting companies interested in a range of market-ready nickel allergy products

Circassia: specialty respiratory pharmaceutical and medical device company

Circassia is building a world-class, specialty pharmaceutical and medical device company focused on respiratory disease and we have our own direct sales and support infrastructure in US, UK and Germany, and we are expanding our team in China where we expect to have 90 people in place by the end of 2018.

We have a collaboration with AstraZeneca in the US to market Tudorza (aclinidium DPI) for COPD and expect to launch Duaklir (aclidinium/formoterol DPI) in 2019, following the recent filing with FDA.  We also market our own NIOX asthma management devices in 35 markets, either via our own sales teams or distributors.

In-licensing or acquisition targets

We are actively looking for new pharmaceutical products/devices in US, China and Europe.  Our targets are late stage or marketed products that are either in respiratory or allied fields, or which can be supported by a small focused sales team.  We would also consider products that share a common physician call point.

Out licensing opportunities

We are also looking for partners who we can work with to progress our development pipeline that comprises direct substitutes for leading asthma and COPD products, as well as a number of treatments based on novel formulations of currently approved drugs.

Circassia is highly responsive and flexible and is open to a wide range of deal structures from promotion deals through licensing to acqusition.

Circassia: specialty respiratory pharmaceutical and medical device company

Circassia is building a world-class, specialty pharmaceutical and medical device company focused on respiratory disease and we have our own direct sales and support infrastructure in US, UK and Germany, and we are expanding our team in China where we expect to have 90 people in place by the end of 2018.

We have a collaboration with AstraZeneca in the US to market Tudorza (aclinidium DPI) for COPD and expect to launch Duaklir (aclidinium/formoterol DPI) in 2019, following the recent filing with FDA.  We also market our own NIOX asthma management devices in 35 markets, either via our own sales teams or distributors.

In-licensing or acquisition targets

We are actively looking for new pharmaceutical products/devices in US, China and Europe.  Our targets are late stage or marketed products that are either in respiratory or allied fields, or which can be supported by a small focused sales team.  We would also consider products that share a common physician call point.

Out licensing opportunities

We are also looking for partners who we can work with to progress our development pipeline that comprises direct substitutes for leading asthma and COPD products, as well as a number of treatments based on novel formulations of currently approved drugs.

Circassia is highly responsive and flexible and is open to a wide range of deal structures from promotion deals through licensing to acqusition.